5523-37-5 ((15S,16E)-16,17,20,21-四去氢-16-甲酰基-18,19-开环育亨宾-19-酸甲酯,Vallesiachotamine)

(Z)-vallesiachotamine;16-formyl-18,19-seco-yohimb;isovallesiachotamine;Methyl -2--1,2,6,7,12,12b-hexahydroindoloquinolizine-3-carboxylate;vallesiachotamine;(15S,16E)-16,17,20,21-Tetradehydro-16-formyl-18,19-secoyohimban-19-oic acid methyl ester;methyl (2S)-2-[(E)-1-oxobut-2-en-2-yl]-1,2,6,7,12,12b-hexahydroindolo[2,3-a]quinolizine-3-carboxylate;(-)-Isovallesiachotamin;(+)-Vallesiachotamin;18,19-Secoyohimban-19-oic acid,16,17,20,21-tetradehydro-16-formyl-,methyl ester,(15beta,16E);VALLESIACHOTAMINE K106;NSC338699;SCHEMBL20943621;CHEMBL454571;(2S,12betaS)-methyl 2-[(1E)-1-formyl-1-propenyl]-1,2,6,7,12,12b-hexahydroindolo[2,3-alpha]quinolizine- 3-carboxylic acid;NSC-338699;FS-7866;5523-37-5;(2S,12betaS)-methyl 2-[(1E)-1-formyl-1-propenyl]-1,2,6,7,12,12b-hexahydroindolo[2,3-alpha]quinolizine-3-carboxylic acid;(2S,12betaS)-methyl 2-((1E)-1-formyl-1-propenyl)-1,2,6,7,12,12b-hexahydroindolo(2,3-alpha)quinolizine-3-carboxylic acid;methyl (2S,12bS)-2-[(E)-1-oxobut-2-en-2-yl]-1,2,6,7,12,12b-hexahydroindolo[2,3-a]quinolizine-3-carboxylate;methyl (2S,12bS)-2-((E)-1-oxobut-2-en-2-yl)-1,2,6,7,12,12b-hexahydroindolo(2,3-a)quinolizine-3-carboxylate;

NTVLUSJWJRSPSM-JXSBNBLESA-N

1S/C21H22N2O3/c1-3-13(12-24)16-10-19-20-15(14-6-4-5-7-18(14)22-20)8-9-23(19)11-17(16)21(25)26-2/h3-7,11-12,16,19,22H,8-10H2,1-2H3/b13-3-/t16-,19-/m0/s1

O(C([H])([H])[H])C(C1=C([H])N2C([H])([H])C([H])([H])C3C4=C([H])C([H])=C([H])C([H])=C4N([H])C=3[C@]2([H])C([H])([H])[C@@]1([H])/C(/C([H])=O)=C(/[H])\C([H])([H])[H])=O